By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Choose which cookies you allow
Necessary Required for the site to work, such as remembering this choice. Always active

AASLD Logo
IDSA Logo
Resource Library
  • Home
    • Table of Contents
    • Introductions
    • Methods
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
  • Test, Evaluate, Monitor
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
  • Treatment-Naive
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
    • Genotype 1
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
    • Genotype 2
      • GT2: No Cirrhosis
      • GT2: Compensated
    • Genotype 3
      • GT3: No Cirrhosis
      • GT3: Compensated
    • Genotype 4
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
  • Treatment-Experienced Patients
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
  • Unique & Key Populations
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
    • PWID, MSM & Corrections
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
  • About
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
AASLD Logo
IDSA Logo
    • Table of Contents
    • Introductions
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
      • GT2: No Cirrhosis
      • GT2: Compensated
      • GT3: No Cirrhosis
      • GT3: Compensated
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
Resource Library
  • Characteristics of patients with dual infection by hepatitis B and C viruses

    May 3, 2017
  • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C

    May 3, 2017
  • Progression of fibrosis in chronic hepatitis C

    May 3, 2017
AASLD Logo
IDSA Logo
  • Test, Evaluate, Monitor
  • Treatment-Naive
  • Treatment-Experienced Patients
  • Key Populations With HCV Infection
  • Resource Library
  • About Us
  • Announcements
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Accessibility

© 2025 HCV Guidelines All right reserved.

Website by Yoko Co